PURPOSE: To evaluate cell survival and tumorigenicity of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) transplantation in immunocompromised nude rats. Cells were transplanted as a cell suspension (CS) or as a polarized monolayer plated on a parylene membrane (PM). METHODS: Sixty-nine rats (38 male, 31 female) were surgically implanted with CS (n = 33) or PM (n = 36). Cohort subsets were killed at 1, 6, and 12 months after surgery. Both ocular tissues and systemic organs (brain, liver, kidneys, spleen, heart, and lungs) were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Every fifth section was stained with hematoxylin and eosin and analyzed histologically. Adjacent sections were processed for immunohistochemical analysis (as needed) using the following antibodies: anti-RPE65 (RPE-specific marker), anti-TRA-1-85 (human cell marker), anti-Ki67 (proliferation marker), anti-CD68 (macrophage), and anti-cytokeratin (epithelial marker). RESULTS: The implanted cells were immunopositive for the RPE65 and TRA-1-85. Cell survival (P = 0.006) and the presence of a monolayer (P < 0.001) of hESC-RPE were significantly higher in eyes that received the PM. Gross morphological and histological analysis of the eye and the systemic organs after the surgery revealed no evidence of tumor or ectopic tissue formation in either group. CONCLUSIONS: hESC-RPE can survive for at least 12 months in an immunocompromised animal model. Polarized monolayers of hESC-RPE show improved survival compared to cell suspensions. The lack of teratoma or any ectopic tissue formation in the implanted rats bodes well for similar results with respect to safety in human subjects.
PURPOSE: To evaluate cell survival and tumorigenicity of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) transplantation in immunocompromised nude rats. Cells were transplanted as a cell suspension (CS) or as a polarized monolayer plated on a parylene membrane (PM). METHODS: Sixty-nine rats (38 male, 31 female) were surgically implanted with CS (n = 33) or PM (n = 36). Cohort subsets were killed at 1, 6, and 12 months after surgery. Both ocular tissues and systemic organs (brain, liver, kidneys, spleen, heart, and lungs) were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Every fifth section was stained with hematoxylin and eosin and analyzed histologically. Adjacent sections were processed for immunohistochemical analysis (as needed) using the following antibodies: anti-RPE65 (RPE-specific marker), anti-TRA-1-85 (human cell marker), anti-Ki67 (proliferation marker), anti-CD68 (macrophage), and anti-cytokeratin (epithelial marker). RESULTS: The implanted cells were immunopositive for the RPE65 and TRA-1-85. Cell survival (P = 0.006) and the presence of a monolayer (P < 0.001) of hESC-RPE were significantly higher in eyes that received the PM. Gross morphological and histological analysis of the eye and the systemic organs after the surgery revealed no evidence of tumor or ectopic tissue formation in either group. CONCLUSIONS: hESC-RPE can survive for at least 12 months in an immunocompromised animal model. Polarized monolayers of hESC-RPE show improved survival compared to cell suspensions. The lack of teratoma or any ectopic tissue formation in the implanted rats bodes well for similar results with respect to safety in human subjects.
Authors: P J Coffey; S Girman; S M Wang; L Hetherington; D J Keegan; P Adamson; J Greenwood; R D Lund Journal: Nat Neurosci Date: 2002-01 Impact factor: 24.884
Authors: Ilene K Sugino; Qian Sun; Jianqiu Wang; Celia F Nunes; Noounanong Cheewatrakoolpong; Aprille Rapista; Adam C Johnson; Christopher Malcuit; Irina Klimanskaya; Robert Lanza; Marco A Zarbin Journal: Invest Ophthalmol Vis Sci Date: 2011-07-01 Impact factor: 4.799
Authors: Yuntao Hu; Laura Liu; Bo Lu; Danhong Zhu; Ramiro Ribeiro; Bruno Diniz; Padmaja B Thomas; Ashish K Ahuja; David R Hinton; Yu-Chong Tai; Sherry T Hikita; Lincoln V Johnson; Dennis O Clegg; Biju B Thomas; Mark S Humayun Journal: Ophthalmic Res Date: 2012-08-03 Impact factor: 2.892
Authors: Eugen Kolossov; Toktam Bostani; Wilhelm Roell; Martin Breitbach; Frank Pillekamp; Jens M Nygren; Philipp Sasse; Olga Rubenchik; Jochen W U Fries; Daniela Wenzel; Caroline Geisen; Ying Xia; Zhongju Lu; Yaqi Duan; Ralf Kettenhofen; Stefan Jovinge; Wilhelm Bloch; Heribert Bohlen; Armin Welz; Juergen Hescheler; Sten Eirik Jacobsen; Bernd K Fleischmann Journal: J Exp Med Date: 2006-09-05 Impact factor: 14.307
Authors: Paul Whiting; Julie Kerby; Peter Coffey; Lyndon da Cruz; Ruth McKernan Journal: Philos Trans R Soc Lond B Biol Sci Date: 2015-10-19 Impact factor: 6.237
Authors: Erin R Burnight; Manav Gupta; Luke A Wiley; Kristin R Anfinson; Audrey Tran; Robinson Triboulet; Jeremy M Hoffmann; Darcey L Klaahsen; Jeaneen L Andorf; Chunhua Jiao; Elliott H Sohn; Malavika K Adur; Jason W Ross; Robert F Mullins; George Q Daley; Thorsten M Schlaeger; Edwin M Stone; Budd A Tucker Journal: Mol Ther Date: 2017-06-12 Impact factor: 11.454
Authors: Biju B Thomas; Danhong Zhu; Tai-Chi Lin; Young Chang Kim; Magdalene J Seiler; Juan Carlos Martinez-Camarillo; Bin Lin; Yousuf Shad; David R Hinton; Mark S Humayun Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-09-13 Impact factor: 3.117
Authors: Roxanne H Croze; David E Buchholz; Monte J Radeke; William J Thi; Qirui Hu; Peter J Coffey; Dennis O Clegg Journal: Stem Cells Transl Med Date: 2014-07-28 Impact factor: 6.940
Authors: Peter D Westenskow; Toshihide Kurihara; Stephen Bravo; Daniel Feitelberg; Zack A Sedillo; Edith Aguilar; Martin Friedlander Journal: J Vis Exp Date: 2015-01-23 Impact factor: 1.355
Authors: Lyndon da Cruz; Kate Fynes; Odysseas Georgiadis; Julie Kerby; Yvonne H Luo; Ahmad Ahmado; Amanda Vernon; Julie T Daniels; Britta Nommiste; Shazeen M Hasan; Sakina B Gooljar; Amanda-Jayne F Carr; Anthony Vugler; Conor M Ramsden; Magda Bictash; Mike Fenster; Juliette Steer; Tricia Harbinson; Anna Wilbrey; Adnan Tufail; Gang Feng; Mark Whitlock; Anthony G Robson; Graham E Holder; Mandeep S Sagoo; Peter T Loudon; Paul Whiting; Peter J Coffey Journal: Nat Biotechnol Date: 2018-03-19 Impact factor: 54.908